20Jan 2017

Cancer cachexia - A review.

  • Professor, department of oral medicine and radiology, Peoples college of dentistry, Bhopal. 2. People\'s college of dental sciences and research center, Bhopal.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Cachexia is considered as a complex interplay of metabolic and behavioral parameters leading to deteriorated quality of life. In recent years many efforts by researchers and clinicians were made to improve our knowledge of cachexia. Cancer and many other chronic or end-stage diseases like AIDS, chronic obstructive pulmonary disease, rheumatoid arthritis, tuberculosis are associated with cachexia, a condition associated with weight loss and alteration in body composition. Cachexia in cancer is generally neglected and contributes to the poor prognosis. A more meticulous understanding of cachexia is needed that probably will lead to combination therapies being developed. Although its prevalence is less, it is a growing problem in Asia. This review is based on the computer-aided Pubmed database and general search for the term “cancer cachexia”. Available free articles related to the pathophysiology, diagnosis and possible treatment modalities in cancer cachexia were downloaded for the review.

  1. Inui A. Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer research1999; 59, 4493–4501
  2. Fearon KC, Carter DC. Cancer cachexia. Annals of Surgery.1988:208; 1-5
  3. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clinical Nutrition. 2008:27;793-799
  4. Tisdale MJ. Biology of cachexia. J Natl Cancer Inst 1997:89; 1763–1773
  5. Brown DR, Berkowitz DE, Breslow MJ. Weight loss is not associated with hyperleptinemia in humans with pancreatic cancer. J Clin Endocrinol Metab, 2001; 86: 162-166
  6. Tisdale MJ. Pathogenesis of cancer cachexia. J Support Oncol 2003; 1:159–168
  7. Kerem M, Ferahkose Z, Yilmaz UT, Pasaoglu H, Ofluoglu E, Bedirli A, et al. Adipokines and ghrelin in gastric cancer cachexia. World J Gastroenterol. 2008; 14: 3633-3641
  8. Kotler DP. Cachexia. Ann Int Med 2001; 133: 622–34
  9. Martignoni ME, Kunze P, Helmut, Friess H. Cancer cachexia. Molecular Cancer 2003, 2:36
  10. Agustsson T, Ryden M, Hoffstedt J, van Harmelen V, Dicker A, Laurencikiene J, et al.Mechanism of increased lipolysis in cancer cachexia. Cancer Res 2007; 67:5531–5537
  11. Tisdale MJ. Cancer cachexia. Br. J. Cancer.1999; 63:337-342
  12. Wiseman G, Ghadially FN. A biochemical concept of tumour growth, infiltration, and cachexia. British medical journal. 1958; 18-21
  13. Theologides A. Anorexia-producing intermediary metabolites. J. Clin. Nutr. 1976; 29: 552-558
  14. Morrison SD. Origins of anorexia in neoplastic disease. J. Clin. Nutr. 1978: 311 104-1 107.
  15. DeWys WD. Pathophysiology of cancer cachexia: current understanding and areas for future research. Cancer Research (Suppl.) 1982;42: 721S-726S
  16. Taylor DD, Gercel-Taylor C, Jenis LG, Devereux DF. Identification of a human tumor-derived lipolysis-promoting factor. Cancer Research. 1992; 52: 829-834
  17. Kern PA. Recombinant human tumor necrosis factor does not inhibit lipoprotein lipase in primary cultures of isolated human adipocytes. J Lipid Res.1988;29: 909-914
  18. Vissers YLJ, Cornelis Dejong CHC, Luiking YC, Fearon KCH, von Meyenfeldt MF, Deutz NEP. Plasma arginine concentrations are reduced in cancer patients: evidence for arginine deficiency? Am J Clin Nutr. 2005; 81:1142–1146
  19. Acharyya S, Guttridge DC. Cancer cachexia signaling pathways continue to emerge yet much still points to the proteasome. Clin Cancer Res 2007;13:1356-1361
  20. Edelman MJ, Gandara DR, Meyers FJ, Ishii R , O’Mahony M, Uhrich M, et al. Serotonergic blockade in the treatment of the cancer anorexia-cachexia syndrome. Cancer 1999; 86:684–688
  21. Fouladiun M, Korner U, Bosaeus I, Daneryd P, Hyltander A, Lundholm KG. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care—correlations with food intake, metabolism, exercise capacity, and hormones. Cancer 2005; 103:2189–2198
  22. Fearon KC, Voss AC, Deborah S, Hustead DS. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 2006; 83:1345–1350
  23. Ogata E. Parathyroid hormone-related protein as a potential target of therapy for cancer-associated morbidity. Cancer. 2000;88:2909–11
  24. Richey LM, George JR, Couch ME, Kanapkey BK, Yin X, Cannon T, et al. Defining cancer cachexia in head and neck squamous cell carcinoma. Clin Cancer Res. 2007; 13: 6562-6567
  25. Garcia JM, Garcia-Touza M, Hijazi RA, Taffet G, Epner D, Mann D, et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J. Clin. Endocrinol. Metab. 2005 90:2920-2926
  26. Mantovani G, Proto E, Massa E, Mulas C, Madeddu C, Mura L, et al. Induction chemotherapy followed by concomitant chemoradiation in advanced head and neck cancer: a phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicity. Int J Oncol 2002; 20: 419–427
  27. Daneryd P, Svanberg E, Korner U, Lindholm E, Sandstrom R, Brevinge H, et al. Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: a randomized prospective study. Cancer Research, 1998; 58. 5374-5379
  28. Trikha M, Corringham R, Klein B, Rossi J. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res. 2003; 9: 4653–4665
  29. Garcia JM, Polvino WJ. Effect on Body Weight and Safety of RC-1291, a Novel, Orally Available Ghrelin Mimetic and Growth Hormone Secretagogue: Results of a Phase I, Randomized, Placebo-Controlled, Multiple-Dose Study in Healthy Volunteers. The Oncologist 2007;12: 594–600
  30. Lundholm K, Korner U, Gunnebo L, Sixt-Ammilon P, Fouladiun M, Daneryd P, et al. Insulin Treatment in Cancer Cachexia: Effects on Survival, Metabolism, and Physical Functioning. Clin Cancer Res 2007; 13: 2699-2706
  31. Strasser F, Lutz TA, Maeder MT, Thuerlimann B, Bueche D, Tscho M, et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer (2008) 98, 300–308.
  32. Qi F, Li A, Inagaki Y, Gao J, Jijun Li, Kokudo N, et al. Chinese herbal medicines as adjuvant treatment during chemo or radio-therapy for cancer. BioScience Trends. 2010; 4: 297-307
  33. Ross DD, Alexander CS. Management of Common Symptoms in Terminally Ill Patients: Part I. Fatigue, Anorexia, Cachexia, Nausea and Vomiting. Am Fam Physician 2001; 64:807-14.
  34. Bruera E, Neumann CM. Management of specific symptom complexes in patients receiving palliative care. CMAJ 1998; 158:1717-26
  35. TaziEM, H Errihani H. Treatment of Cachexia in Oncology.indian J Palliat Care. 2010 Sep–Dec; 16(3): 129–137
  36. Gordon JN, Goggin PM. Thalidomide and its derivatives: emerging from the wilderness. Postgrad Med J 2003; 79:127–132
  37. Argilés JM, Olivan M, Busquets S, López-Soriano FJ. Optimal management of cancer anorexia–cachexia syndrome. Cancer Management and Research 2010:2; 27–38
  38. Eleutherakis-Papaiakovou V, Bamias A, Dimopoulos MA. Thalidomide in cancer medicine. Annals of Oncology. 2004; 15: 1151–1160
  39. Bruera E, Neumann CM, Pituskin E, Calder K, Ball G, Hanson J. Thalidomide in patients with cachexia due to terminal cancer: Preliminary report. Annals of Oncology. 1999; 10: 857-859
  40. Dewey A, Baughan C, Dean TP, Higgins B, Johnson I. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database of Systematic Reviews. 2007, Issue 1
  41. Giacosa A, Rondanelli M. Fish oil and treatment of cancer cachexia. Genes Nutr. 2008;3: 25–28
  42. Gonçalves DC, Lira FS, Carnevali (Jr) LC, Rosa JC, Pimentel GD, Seelaender M. Conjugated linoleic acid: good or bad nutrient. Diabetology and Metabolic Syndrome. 2010: 2: 62.
  43. Simons JPFHA, Schols AMWJ, Janine MJ, Hoefnagels JMJ, Westerterp KR, ten Velde GPM, et al. Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer- a randomized, placebo-controlled trial. Cancer 1998; 82:553–560
  44. Maltoni M, Nanni O, Scarpi E, Rossi D, Serra P, Amadori D. High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: A systematic review of randomised clinical trials. Annals of Oncology. 2001; 12: 289-300
  45. Dev R, Fabbro ED, Bruera E. Association between megestrol acetate treatment and symptomatic adrenal insufficiency with hypogonadism in male patients With Cancer. Cancer 2007; 110:1173–1177
  46. Couluris M, Mayer JLR, Freye DR, Sandler E, Xu P, Krischer JP. The effect of cyproheptadine hydrochloride (Periactin®) and megestrol acetate (Megace®) on weight in children with cancer/treatment-related cachexia. J Pediatr Hematol Oncol. 2008 November; 30(11): 791–797
  47. Dickerson JWT. Nutrition in the cancer patient: a review. Journal of the Royal Society of Medicine.1984, 77:309-315
  48. Souba WW, Edward M. Copeland Ill EM. Hyperalimentation in cancer. CA Cancer J Clin 1989; 39; 105-114
  49. Dudrick SJ, MacFadyen, Jr. BV, Souchon EA, Englert DM, Copeland Ill EM. Parenteral nutrition techniques in cancer patients. Cancer Research, 1977; 37, 2440-2450
  50. Lundholm K, Daneryd P, Ingvar Bosaeus I, Korner U, Lindholm E. Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: effects on survival, metabolism, and function a randomized prospective study. Cancer 2004; 100:1967–1977
  51. Bozzetti F, Migliavacca S, Pupa A, Ammatuna M, Bonalumi MG, Terno G, et al. Total Parenteral Nutrition Prevents Further Nutritional Deterioration in Patients with Cancer Cachexia. Ann. Surg. 1987; 205(2): 138-143
  52. Vigano A, Donaldson N, Higginson IJ, Bruera E, Mahmud S, Suarez-Almazor M. Quality of life and survival prediction in terminal cancer patients a multicenter study. Cancer 2004; 101:1090–1098
  53. Drasin H, Rosenbaum EH, Stitt CA, Rosenbaum IR. The challenge of nutritional maintenance in cancer patients. West J Med. 1979; 130:145-152
  54. Davis CL, Hardy JR. Palliative care. BMJ 1994; 308:1359-1362
  55. Smith GF, Toonen TR. Primary Care of the Patient with Cancer. Am Fam Physician. 2007; 75: 1207-1214.

[Harshkant P Gharote, Anuja Gupta and Sahil Kohli. (2017); Cancer cachexia - A review. Int. J. of Adv. Res. 5 (Jan). 396-401] (ISSN 2320-5407). www.journalijar.com

Dr. Anuja Gupta
People\\\'s University

DOI:

Article DOI: 10.21474/IJAR01/2759      
DOI URL: http://dx.doi.org/10.21474/IJAR01/2759

Download Full Paper

Download PDF No. of Downloads: 51 | No. of Views: 131